Fig. 1From: Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational studyStudy profile. ER, estrogene receptor; HER2, human epidermal growth factor receptor 2; PPI, proton pump inhibitorBack to article page